Biotech News

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics (ABEO)Abeona TherapeuticsClinical readout

November 10, 2026 7:30am EST

CLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2026:

Stifel 2026 Healthcare Conference: Fireside chat on Wednesday November 11, 2026, at 8:40 AM Eastern Time (ET) and investor meetings.

Jefferies Global Healthcare Conference: Presentation on Wednesday, November 18, 2026, at 10:30 AM Greenwich Mean Time (GMT) and investor meetings.

Live webcasts of the fireside chat and Company presentation can be accessed on the Investors section of the Abeona website under “Events” at https://investors.abeonatherapeutics.com/events , where replays of available events will also be accessible for a limited time.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company building a portfolio of therapies for rare and serious diseases with multiple opportunities for value creation. The Company’s portfolio includes ZEVASKYN ® (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa; ABO-801, a Phase 3-ready product candidate for eosinophilic esophagitis; and ABO-701 (PSMA-SIR-T™), an investigational engineered T-cell therapy targeting PSMA. For more information, visit www.abeonatherapeutics.com .

ZEVASKYN ® , Abeona Assist ® , Abeona Therapeutics ® , and their related logos are trademarks of Abeona Therapeutics Inc.

Contacts: Investor and Media: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor: Lee M. Stern Meru Advisors [email protected]

Source: Abeona Therapeutics Inc. Released November 10, 2026

Related news

ABEOAbeona Therapeutics2026-11-09 11:30 EST

Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement

NTLAIntellia2026-11-03 13:00 EST

Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations

NTLAIntellia2026-11-12 15:00 EST

Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026

CRSPCRISPR Therapeutics2026-11-04 14:01 EST

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

TARAProtara Therapeutics2026-10-15 12:00 EST

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

CRSPCRISPR Therapeutics2026-10-08 12:30 EST

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

ABEOAbeona Therapeutics2026-11-09 11:35 EST

Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress

CAPRCapricor Therapeutics2026-11-09 14:00 EST

Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology

MNPRMonopar2026-11-02 13:00 EST

Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

ARWRArrowhead Pharmaceuticals2026-11-02 12:30 EST

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Abeona Therapeutics

Cell and Gene Therapy Company Abeona Therapeutics develops and commercializes genetic medicines for serious diseases. ZEVASKYN ZEVASKYN is an autologous, gene-corrected epidermal sheet therapy for wounds in recessive dystrophic epidermolysis bullosa and provides Abeona with a commercial cell-therapy platform. ABO-701 ABO-701 is an...

Recent company news

Stock data

Close
2.45 USD
Market cap
324.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States